WuXi Biologics announced that based on the preliminary assessment of the unaudited consolidated management accounts of the company for the year ended December 31, 2017, the company is expected to record an increase of approximately 75% to 80% in its net profit from RMB 141 million for the year ended December 31, 2016 to an amount of approximately RMB 247 million to RMB 254 million for the year ended December 31, 2017. During the reporting period, the company incurred an unrealized foreign exchange loss due to a translation loss from the IPO proceeds (in U.S. Dollar) to Renminbi as a result of Renminbi appreciation against the U.S. Dollar. If the unrealized foreign exchange loss is excluded, the company's net profit for the year ended December 31, 2017 is expected to be approximately RMB 321 million to RMB 328 million, representing a year-on-year growth of approximately 128% to 133%. Such an increase was primarily attributable to a strong growth in revenue driven by implementing the Company's "follow-the-molecule" strategy, and efficiency enhancement of the Company's business operation.